Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221002577> ?p ?o ?g. }
- W4221002577 endingPage "330" @default.
- W4221002577 startingPage "330" @default.
- W4221002577 abstract "VEGF plays a crucial role in cancer development, angiogenesis and progression, principally liver and breast cancer. It is vital to uncover novel chemical candidates of VEGFR inhibitors to develop more potent anti-breast and anti-liver cancer agents than the currently available candidates, sorafenib and regorafenib, that face resistance obstacles and severe side effects. Herein, nine pyrazolopyrimidine derivatives were designed, synthesized as sorafenib and regorafenib analogues and screened for their in vitro cytotoxic and growth inhibition activities against four human cancer cell lines, namely breast cancer (Michigan Cancer Foundation-7 (MCF-7), hepatocellular carcinoma (HCC) type (HepG2), lung carcinoma (A-549) and human colorectal carcinoma-116 (HCT-116)). Among the tested compounds, compounds 1, 2a, 4b and 7 showed the uppermost cytotoxic activities against all aforementioned cell lines with IC50 estimates varying from 6 to 50 µM, among which compound 7 showed the best inhibitory activity on all tested compounds. Stunningly, compound 7 showed the best significant inhibition of the VEGFR-2 protein expression level (72.3%) as compared to the control and even higher than that produced with sorafenib and regorafenib (70.4% and 55.6%, respectively). Modeling studies provided evidence for the possible interactions of the synthesized compounds with the key residues of the ATP binding sites on the hinge region and the “DFG out” motif of VEGFR-2 kinase. Collectively, our present study suggests that pyrazolopyrimidine derivatives are a novel class of anti-cancer drug candidates to inhibit VEGF-VEGFR function. Aspiring to promote constrained aqueous solubility, hence poor oral bioavailability of the developed lead molecule, 7 and 2a-charged D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) surface-coated niosomes were successfully constructed, adopting a thin film hydration technique striving to overcome these pitfalls. A 23 full factorial design was involved in order to investigate the influence of formulation variables: type of surfactant, either Span 60 or Span 40; surfactant:cholesterol ratio (8:2 or 5:5) along with the amount of TPGS (25 mg or 50 mg) on the characteristics of the nanosystem. F2 and S2 were picked as the optimum formula for compounds 2a and 7 with desirability values of 0.907 and 0.903, respectively. In addition, a distinguished improvement was observed in the compound’s oral bioavailability and cytotoxic activity after being included in the nano-TPGS-coated niosomal system relative to the unformulated compound. The nano-TPGS-coated niosomal system increased the hepatocellular inhibitory activity four times fold of compound 7a (1.6 µM) and two-fold of 2a (3 µM) relative to the unformulated compounds (6 µM and 6.2 µM, respectively)." @default.
- W4221002577 created "2022-04-03" @default.
- W4221002577 creator A5021277079 @default.
- W4221002577 creator A5058171245 @default.
- W4221002577 creator A5070260885 @default.
- W4221002577 creator A5074213732 @default.
- W4221002577 creator A5087866154 @default.
- W4221002577 date "2022-03-09" @default.
- W4221002577 modified "2023-10-18" @default.
- W4221002577 title "Design, Green Synthesis and Tailoring of Vitamin E TPGS Augmented Niosomal Nano-Carrier of Pyrazolopyrimidines as Potential Anti-Liver and Breast Cancer Agents with Accentuated Oral Bioavailability" @default.
- W4221002577 cites W1195955210 @default.
- W4221002577 cites W127170651 @default.
- W4221002577 cites W1276566291 @default.
- W4221002577 cites W1416958482 @default.
- W4221002577 cites W171349864 @default.
- W4221002577 cites W1971837077 @default.
- W4221002577 cites W1988144726 @default.
- W4221002577 cites W1992905076 @default.
- W4221002577 cites W1994193851 @default.
- W4221002577 cites W2006027632 @default.
- W4221002577 cites W2022665891 @default.
- W4221002577 cites W2026420898 @default.
- W4221002577 cites W2049086737 @default.
- W4221002577 cites W2061345986 @default.
- W4221002577 cites W2063544208 @default.
- W4221002577 cites W2067216473 @default.
- W4221002577 cites W2067745599 @default.
- W4221002577 cites W2072666583 @default.
- W4221002577 cites W2093086017 @default.
- W4221002577 cites W2153484787 @default.
- W4221002577 cites W2186910186 @default.
- W4221002577 cites W2293809486 @default.
- W4221002577 cites W2319506065 @default.
- W4221002577 cites W2397876963 @default.
- W4221002577 cites W2528451823 @default.
- W4221002577 cites W2598230851 @default.
- W4221002577 cites W2743986386 @default.
- W4221002577 cites W2767557552 @default.
- W4221002577 cites W2782134028 @default.
- W4221002577 cites W2782690276 @default.
- W4221002577 cites W2790092507 @default.
- W4221002577 cites W2794170219 @default.
- W4221002577 cites W2794612623 @default.
- W4221002577 cites W2807203217 @default.
- W4221002577 cites W2900676756 @default.
- W4221002577 cites W2949240503 @default.
- W4221002577 cites W2950977232 @default.
- W4221002577 cites W2955126426 @default.
- W4221002577 cites W2967089531 @default.
- W4221002577 cites W2967351647 @default.
- W4221002577 cites W2969621410 @default.
- W4221002577 cites W2981810096 @default.
- W4221002577 cites W2998567095 @default.
- W4221002577 cites W3005200342 @default.
- W4221002577 cites W3011716586 @default.
- W4221002577 cites W3037255929 @default.
- W4221002577 cites W3092270666 @default.
- W4221002577 cites W3110732212 @default.
- W4221002577 cites W3114455846 @default.
- W4221002577 cites W3126486277 @default.
- W4221002577 cites W3137055941 @default.
- W4221002577 cites W3163960271 @default.
- W4221002577 cites W3166272851 @default.
- W4221002577 cites W3201610628 @default.
- W4221002577 cites W4243326970 @default.
- W4221002577 doi "https://doi.org/10.3390/ph15030330" @default.
- W4221002577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35337128" @default.
- W4221002577 hasPublicationYear "2022" @default.
- W4221002577 type Work @default.
- W4221002577 citedByCount "13" @default.
- W4221002577 countsByYear W42210025772022 @default.
- W4221002577 countsByYear W42210025772023 @default.
- W4221002577 crossrefType "journal-article" @default.
- W4221002577 hasAuthorship W4221002577A5021277079 @default.
- W4221002577 hasAuthorship W4221002577A5058171245 @default.
- W4221002577 hasAuthorship W4221002577A5070260885 @default.
- W4221002577 hasAuthorship W4221002577A5074213732 @default.
- W4221002577 hasAuthorship W4221002577A5087866154 @default.
- W4221002577 hasBestOaLocation W42210025771 @default.
- W4221002577 hasConcept C121608353 @default.
- W4221002577 hasConcept C126322002 @default.
- W4221002577 hasConcept C181389837 @default.
- W4221002577 hasConcept C185592680 @default.
- W4221002577 hasConcept C2776231280 @default.
- W4221002577 hasConcept C2776248978 @default.
- W4221002577 hasConcept C2778019345 @default.
- W4221002577 hasConcept C2778695046 @default.
- W4221002577 hasConcept C2780394083 @default.
- W4221002577 hasConcept C502942594 @default.
- W4221002577 hasConcept C526805850 @default.
- W4221002577 hasConcept C530470458 @default.
- W4221002577 hasConcept C71924100 @default.
- W4221002577 hasConcept C96232424 @default.
- W4221002577 hasConcept C98274493 @default.
- W4221002577 hasConceptScore W4221002577C121608353 @default.
- W4221002577 hasConceptScore W4221002577C126322002 @default.
- W4221002577 hasConceptScore W4221002577C181389837 @default.
- W4221002577 hasConceptScore W4221002577C185592680 @default.